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When will we have an effective vaccine against SARS-CoV-2? There can be few questions with more 
profound implications for what life will look like over the coming years. 
 
On one hand, there is a blunt and unsatisfying answer: until the results of large-scale efficacy trials 
are available, we simply cannot know. On the other hand, there is cause for optimism. This year has 
seen a remarkable mobilisation of resources, ingenuity, and dedication from vaccine researchers 
across the globe. Over 200 vaccine candidates are in development, and Phase III efficacy trials are 
either underway, or imminent, for nine candidates spanning three different vaccine platforms.  
 
Things are moving quickly. In response to the almost daily questions about process and progress 
asked by stakeholders in academia, media, politics, and the public, the Vaccine Centre at the London 
School of Hygiene & Tropical Medicine (VaC) developed an online SARS-CoV-2 vaccine development 
tracker in April 2020 (https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/). 
 
The VaC tracker currently contains three key features, each of which is updated on a weekly basis. 
The Vaccine landscape includes a summary of SARS-CoV-2 vaccine candidates, including platform, 
institutes involved, and phase of development. This pools the latest information from the World 
Health Organization and several other online repositories. We are also very grateful for additional 
information provided directly by vaccine developers, and welcome their continued input in the 
months ahead. 
 
The Clinical trials database summarises key attributes of all registered SARS-CoV-2 vaccine trials, 
including their size, location, study design, enrolment status, and estimated completion date, 
alongside links to clinical protocols. This resource now includes information for over 75 registered 
trials, and new studies continue to be added.  
 
Finally, as trials progress through the development phases, safety and immunogenicity data are 
becoming available on a larger scale. These need to be interpreted carefully. While reports that 
“vaccine X induced an immune response” are common in media coverage, not all immune responses 
are created equal. In August, we launched a Living review that distils the results of clinical trials as 
they become available. This includes a comprehensive and accessible presentation of antibody and 
T-cell response data. Comparing findings across trials will remain a challenge due to differences in 
study design, lab methods, and myriad other factors, but having all of the relevant results in the 
same place is a useful starting point. 
 
Many challenges lie ahead. While we can hope that a safe and highly effective vaccine will emerge 
from the fray, we must also prepare for a situation in which we have multiple partially protective 
SARS-CoV-2 vaccines, conferring immunity that wanes over time. Phase III efficacy trials will tell us 
more, but they are not the end of the story. Stringent monitoring for safety, effectiveness, and 
durability of protection will be essential as the number of vaccinated individuals grows. 
 
Our tracker will adapt and expand to meet the demands of this evolving field. We plan to add new 
features monitoring the status and results of efficacy trials, as well as the challenges associated with 
distributing limited vaccine supplies in an equitable way.  
 
The VaC is not directly involved in the development of any vaccines, leaving us ideally placed to 
provide an independent academic voice on SARS-CoV-2 vaccine development. Our motto is “Bringing 
vaccine research together”, and we hope that our tool does just that by supplying objective and 
freely accessible information in the midst of the global crisis. 
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